Гелофузин

Quick links

Choose a section

Quick links to important sections

Advertisements

Гелофузин

Advertisements
Advertisements

Treatment option: Hypovolemia

Advertisements

Overview of Гелофузин

Quick Facts about Гелофузин

Property Description
Active Ingredient Succinylated Gelatin (Modified Fluid Gelatin)
Form Solution for Infusion
Pharmacological Class Blood Substitutes and Plasma Protein Fractions (Colloidal Volume Expander)
Common Use Rapid restoration of circulating fluid volume
Origin Derived (Modified biological substance)

What is Гелофузин and What Class Does It Belong To?

Гелофузин is an essential, prescription medicine administered as an intravenous solution (drip) in clinical settings. It is formally classified as a Plasma Volume Substitute or Volume Expander, meaning its purpose is to replace lost fluid volume in the circulatory system. This places it in the high-level pharmacological category of Blood Substitutes and Plasma Protein Fractions. As a colloid solution, it contains large molecules that distinguish it from simpler electrolyte solutions, allowing it to maintain volume in the blood vessels more effectively. Гелофузин is clinically recognized for its use as a first-line treatment in the acute management of volume deficit.

What is Гелофузин Made Of and How is it Administered?

The core active ingredient in the solution is Succinylated Gelatin, often referred to as Modified Fluid Gelatin. This substance is a protein that has been chemically modified to ensure stability and compatibility in the body. The active gelatin is contained within a base of balanced salts and sterile Water for Injections.

Gelatin-based solutions are effective agents for immediate volume resuscitation in cases of hypovolemia. This characteristic supports the medicine's general use in rapidly stabilizing a patient's circulation. Гелофузин, manufactured by B. Braun, is designed to be easily stored and rapidly administered, making it a reliable solution for emergency medical use.

What is the General Purpose of Гелофузин?

The general purpose of Гелофузин is to quickly and temporarily restore the total circulating fluid volume in the body to stabilize the patient's condition. The modified gelatin works to hold fluid within the blood vessels, acting as a rapid Volume Booster to support blood pressure and ensure adequate circulation. Modified fluid gelatin products exert a clinically relevant colloid osmotic effect. This indicates that the medicine is designed to be effective at drawing and holding fluid where it is needed—in the bloodstream. It serves as a crucial, immediate measure for stabilizing the cardiovascular system in acute situations involving severe fluid deficit, such as massive blood loss or hypovolemic shock.

Advertisements

What side effects are possible with Гелофузин?

Possible Side Effects and Safety Information for Гелофузин

This section outlines the officially documented adverse reactions and safety characteristics of Succinylated Gelatin, based strictly on government regulatory documents.


Regulatory Classification of Adverse Reactions

The most significant safety characteristic documented for this colloidal volume expander is the potential for hypersensitivity reactions (allergic reactions), which can occur with the first administration of the solution. These reactions are formally classified by frequency:

  • Uncommon (affecting 1 to 10 users in 1,000): Transient mild allergic skin reactions, such as urticaria (hives).
  • Rare (affecting 1 to 10 users in 10,000): Severe anaphylactic/anaphylactoid reactions, including shock. Other rare effects include an increase in heart rate (tachycardia), difficulty breathing (dyspnea), and low blood pressure (hypotension).
  • Very Rare (affecting less than 1 user in 10,000): Severe bradycardia and cardiac arrest have been documented in association with severe hypersensitivity episodes.

The regulatory safety profile also notes non-frequency-classified effects on the Gastrointestinal Disorders system, such as nausea and vomiting (frequency Not Known).


Safety Constraints and Special Populations

Official regulatory texts define several safety constraints (contraindications). The solution must not be used in individuals with known hypersensitivity to gelatin, pre-existing hypervolaemia (circulatory overload), acute congestive cardiac failure, or severe renal insufficiency.

Specific safety considerations exist for certain populations: patients with a history of allergic diseases or chronic asthma are officially noted as being at an increased risk of developing allergic reactions. Throughout administration, careful patient monitoring for signs of anaphylactic/anaphylactoid reactions is specified in the official documents.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The officially documented overdose profile for Гелофузин (Succinylated Gelatin) is primarily defined by the risks associated with the administration of an inappropriate amount or too rapid infusion of the colloidal volume expander.

Overdose may lead to hypervolaemia and circulatory overload, which are officially documented manifestations. Symptoms may include dyspnoea (difficult breathing), headache, and jugular vein congestion. Physiological changes involve electrolyte and acid-base imbalance, and a significant fall in haematocrit and plasma protein concentration due to dilutional effects.

Mandatory Emergency Actions

Official regulatory guidance mandates that immediate medical attention is required when signs of circulatory overload or severe complications are observed. Severe outcomes, such as pulmonary oedema, acute left heart failure, or an anaphylactic/anaphylactoid shock, are life-threatening conditions cited in regulatory texts.

  • Immediate Action: The infusion must be stopped immediately upon detection of overdose symptoms or an adverse reaction.
  • Supportive Measures: Treatment must be symptomatic and supportive. In cases of circulatory overload, the administration of a rapid-acting diuretic is described. Monitoring of electrolytes, acid-base balance, and haemodynamic parameters is required.
  • Antidote: No known specific antidote is documented in the official prescribing information.

Volume overload due to overdose must be strictly avoided, particularly in patients with pre-existing pulmonary or cardiocirculatory problems or impaired renal function, as these conditions increase the risk and severity of severe complications.

Advertisements

Therapeutic Uses of Гелофузин

What Gelofusine treats: main uses and benefits

Gelofusine is a plasma substitute used primarily to restore and maintain circulating blood volume. It belongs to a class of medicines known as colloids, which are designed to remain in the bloodstream for a specific period to stabilize a patient’s hemodynamic status.

Primary Uses

The medication is utilized in clinical settings where there is an acute need to replace fluid loss. This typically occurs in the following scenarios:

  • Hypovolemia: Treatment of low blood volume caused by blood loss, trauma, or surgery.
  • Shock Management: Stabilization of patients experiencing hemorrhagic or traumatic shock to ensure vital organs receive adequate blood flow.
  • Preventative Use: Maintenance of blood pressure during certain medical procedures, such as during the administration of spinal or epidural anesthesia, which can cause a sudden drop in pressure.
  • Extracorporeal Circulation: Used to prime heart-lung machines or dialysis equipment during specialized medical treatments.

How It Works

Gelofusine contains succinylated gelatin, which creates oncotic pressure within the blood vessels. This pressure helps keep fluid inside the vascular system and can even draw excess fluid from the body's tissues back into the blood vessels. This effect helps to:

  • Increase Blood Volume: Rapidly expanding the volume of circulating fluid to compensate for losses.
  • Improve Cardiac Output: By increasing the volume of blood returning to the heart, it helps the heart pump more effectively.
  • Support Tissue Oxygenation: By maintaining adequate blood pressure and flow, it ensures that oxygen reaches the body’s cells and tissues.

Benefits in Clinical Practice

As a colloidal solution, Gelofusine offers specific advantages in acute care. Its molecular structure allows it to stay in the circulation longer than simple salt solutions (crystalloids), which can leak out of the blood vessels more quickly. This sustained volume effect provides clinicians with a predictable tool for stabilizing patients during critical transitions or surgical interventions.

Regulatory References

  1. Irish Health Products Regulatory Authority (HPRA) Information
Advertisements

Eligibility and Restrictions for Use

Who can and cannot use Гелофузин?

This section outlines the official eligibility and restrictions for using Гелофузин, as defined by regulatory documents.

Contraindications (Who Must Not Use)

Гелофузин is contraindicated (must not be used) in patients with:

  • Hypersensitivity (severe allergic reaction) to gelatin-containing solutions or any ingredient in the product.
  • Known allergy to red meat (mammal meat) and offal, or hypersensitivity to the sugar molecule galactose-alpha-1,3-galactose (alpha-Gal).
  • Pre-existing conditions of Hypervolaemia (volume overload) or Hyperhydration.
  • Acute congestive cardiac failure.

Restrictions and Special Considerations

Population Eligibility Status Special Considerations
Paediatric (Children) Not Completely Established Use is not fully established; should only be considered if benefits clearly outweigh potential risks, requiring very careful monitoring.
Elderly (Older Adults) Caution Required Careful dose adjustment is necessary, especially for those with co-occurring diseases like cardiac or renal insufficiency.

In all cases, use is restricted to situations where volume deficit cannot be sufficiently corrected using crystalloid solutions alone. Dosage must be strictly controlled to prevent volume overload, particularly in patients with existing heart or lung problems.

Advertisements

What should I know about interactions with other medicines?

The official regulatory documents for Гелофузин (Succinylated Gelatin) define a specific interaction profile that is centered on the substance’s physical function as a volume expander, rather than metabolic or enzymatic pathways. Pharmacological drug-drug interactions are generally not known.

Documented Pharmacodynamic Interactions

Co-administration with medicinal products that can cause sodium retention is a documented interaction.

Product Categories
Corticosteroids
Non-steroidal Anti-inflammatory Agents (NSAIDs)

Formal Outcome: Concomitant use with these agents may lead to oedema (fluid accumulation) due to an additive effect on sodium and fluid retention. This combination is officially designated as a use-with-caution scenario. The regulatory label does not specify any mandatory timing separation requirements or formally classify any combination as contraindicated based on interaction risk.

Interference with Diagnostic Procedures

The administration of Succinylated Gelatin interacts functionally with specific clinical-chemical tests, which may result in the reporting of falsely high values. The tests affected include the erythrocyte sedimentation rate, the specific gravity of urine, and certain unspecific protein assays, such as the biuret method. This procedural constraint requires awareness when interpreting laboratory results following administration.

Advertisements

Mechanism of Action

Pharmacodynamic Mechanism of Succinylated Gelatin

Гелофузин, a solution of succinylated gelatin, functions as a synthetic colloid for plasma volume expansion. Following intravenous infusion, the modified gelatin macromolecules are retained predominantly within the vascular compartment due to their specific molecular weight and structure (weight average: 26,500 Daltons).

This intravascular retention of the macromolecules establishes a colloid osmotic pressure (COP) that is higher than that of the surrounding interstitial fluid. This physicochemical gradient drives a net osmotic shift, drawing free water and crystalloids from the extravascular space into the capillaries. The resulting increase in circulating plasma volume directly modulates system-level physiological consequences including elevated central venous pressure, increased stroke volume, and enhanced cardiac output. The gelatin is ultimately cleared through renal excretion.

Advertisements

Dosage and Administration Information

General Administration Guidelines for Гелофузин

Гелофузин is a 40 mg/mL solution for infusion containing succinylated gelatin, and its use is strictly reserved for intravenous administration (IV drip) in clinical settings. The dosing regimen is highly individualized, as the volume and rate of administration are continuously adjusted based on the patient's immediate circulatory status and need for volume replacement.


Administration Scope and Dosing

Parameter General Instruction
Route of Administration Strictly Intravenous Infusion (IV).
Dosing Schedule Initial Dose (Adults): Typically 500 mL to 1000 mL, adjusted according to the degree of blood or fluid loss. The dose is titrated based on continuous patient monitoring.
Maximum Dose Physiologically limited by the degree of haemodilution; care must be taken to ensure the haematocrit does not fall below critical values (e.g., 25% to 30%).
Frequency Pattern As-Needed (Acute/On-Demand); administration continues until stable haemodynamic conditions are reached.

Procedural and Population-Specific Conditions

Preparation and Administration Specifics: If rapid infusion is necessary, the solution may be warmed to no more than 37°C prior to use. A crucial procedural instruction requires that the first 20 to 30 mL of the solution must be infused slowly under close observation. In emergency pressure infusion, all air must be removed from the container and infusion set to prevent the risk of air embolism.

Age-Group Administration Rules: No standard posology is established for the paediatric population; administration must be based on a careful assessment and requires especially careful monitoring. Older adults should be administered the solution with caution, as advanced age is often associated with conditions like cardiac or renal insufficiency.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Гелофузин


Evidence for Acute Volume Loss and Blood Loss

Гелофузин was studied for situations where there is a rapid and severe reduction in the circulating fluid volume, a condition known as acute hypovolemia. Research has explored the use of this solution in patients experiencing significant bleeding from trauma or during complex surgical procedures. Studies monitored outcomes related to physiological strain or stress, focusing on the immediate effects on the body.

The studies primarily measured the rate at which the solution contributes to fluid volume and its duration within the blood vessels, which is a metric for plasma volume substitutes. Research includes data showing measurements of short-term volume contribution within the blood vessels. Studies examined whether the solution was associated with hemodynamic stability; research examined whether the solution was associated with changes in blood pressure and heart rate metrics in the short term. Research also examined the need for patients to receive blood transfusions and observed overall survival patterns within the study groups.

Research includes data showing measurements of the short-term volume contribution. However, long-term effects are not fully established. Follow-up durations were limited in many of the key trials, and evidence is often focused on the acute hospital stay.


Evidence for Perioperative Fluid Management

Research has also examined the use of the solution in controlled surgical environments, where it was applied in studies examining short-term symptom patterns related to functional imbalance during and immediately after the operation. Studies explored how the solution performed when used to replace fluids lost during surgery, tracking the overall fluid balance and its effect on key systems, such as the kidneys.

Research highlights changes measured during the study period, including research describing the solution’s measured pattern of remaining in the blood vessels for defined time intervals. The studies monitored the impact on coagulation parameters (the body's ability to clot blood), noting that this solution, like other volume expanders, may be associated with changes in these measurements in a dose-related way.

Measurements of short-term hemodynamic stability were observed in studies tracking changes relative to pre-treatment baselines. Results apply only to the populations studied, which were mainly adults undergoing elective procedures. Comparative evidence is lacking in some areas, and the follow-up durations were limited to the immediate post-operative period.


What Research Gaps and Uncertainties Remain

The existing research, while describing the solution's basic function as a volume expander, presents several recognized gaps. Evidence quality varies across studies, and many trials were underpowered to reliably track differences in major clinical outcomes like mortality or the need for dialysis.

Evidence is limited regarding the definitive long-term consequences of choosing this solution over others for volume resuscitation. Furthermore, findings were mixed in the highly complex setting of sepsis, an area where certainty remains low compared to its use in elective surgery. The research does not determine whether an individual will respond similarly, as findings describe group patterns, not personal outcomes.

Key Studies & References

  1. Gelofusine Irish Summary of Product Characteristics (HPRA)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Гелофузин (FAQ)


Q: Is it safe to use this product during pregnancy?

Official regulatory documents indicate that controlled studies in pregnant women have not been performed. Due to the possibility of severe allergic reactions, its administration is reserved for situations where the need for plasma volume replacement is absolute. The decision to use it during pregnancy is based on a risk-benefit assessment performed by a healthcare professional.


Q: Is it safe to use this product while breastfeeding?

According to the official product information, it is not known whether the active ingredient passes into breast milk. There is currently insufficient clinical experience available regarding the product's use during the breast-feeding period.


Q: Will this product affect my ability to drive or use machines?

The product information does not specify any known effects on a patient's ability to drive vehicles or operate machinery. Its use is restricted to clinical settings, and official information does not list any known negative effects on mental or physical ability.


Q: Does this product contain calcium?

The composition of the solution lists balanced salts, including sodium and chloride, but does not list calcium. Official regulatory text notes that the calcium content is negligible. This composition helps ensure that the product does not interfere with the transfusion of citrated blood.


Q: Can I receive this product if I am taking diuretics (water pills)?

Regulatory documents state that caution should be exercised if this product is given alongside other medicines that can cause the body to retain sodium, such as diuretics. This co-administration may increase the risk of fluid accumulation or swelling, known as oedema.


Q: What is the maximum number of days I can receive this treatment?

The frequency and total duration of the infusion are not based on a set number of days but are determined based on the individual patient's immediate circulatory condition. Treatment continues only until the condition is stable. The maximum daily quantity is restricted due to the potential risk of excessive dilution of the blood.


Q: Is this product safe for a child under 1 year old?

Official warnings state that there is insufficient clinical experience regarding the use of this solution in children, including infants. Therefore, the product is administered only after a careful assessment determines the expected benefits outweigh the potential risks.

Advertisements

How should Гелофузин be stored and disposed of?

Storage and Disposal Requirements for Gelofusine

Gelofusine must be stored under controlled temperature conditions and should not be stored above 25 C.

It is an explicit regulatory requirement that the solution must not be frozen. The product must be kept out of the sight and reach of children.

Handling and Integrity

  • Do not use the solution if any cloudiness or discoloration is noticed, or if the container is leaking.
  • Infusion must commence immediately after connecting the container to the administration set, as the product contains no preservative.
  • Any partially used solution or waste from an opened container must be thrown away and not be reconnected.

Disposal

Medicines should not be disposed of via wastewater or household waste. Disposal of any unused product or waste material must be carried out in accordance with local requirements; patients are instructed to consult their pharmacist for proper disposal methods.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Гелофузин found in:

A-Z Index: